Nomograms for predicting long-term overall survival and cancer-specific survival in lip squamous cell carcinoma: A population-based study

Chuan-Yu Hu1,2 | Zhen-Yu Pan1,3,4 | Jin Yang1,3 | Xiu-Hong Chu5 | Jun Zhang1,3,6 | Xue-Jin Tao2 | Wei-Min Chen2 | Yuan-Jie Li7 | Jun Lyu1,3

1Clinical Research Center, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
2Stomatology Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3School of Public Health, Xi’an Jiaotong University Health Science Center, Xi’an, Shaanxi, China
4Department of Pharmacy, The Affiliated Children Hospital of Xi’an Jiaotong University, Xi’an, Shaanxi, China
5Department of Nursing, Yeda Hospital, Yantai, China
6Department of Orthopaedics, Baoji Municipal Central Hospital, Baoji, China
7Department of Human Anatomy, Histology and Embryology, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center, Xi’an, China

Abstract

Background: The goal of this study was to establish and validate two nomograms for predicting the long-term overall survival (OS) and cancer-specific survival (CSS) in lip squamous cell carcinoma (LSCC).

Methods: This study selected 4175 patients who were diagnosed with LSCC between 2004 and 2015 in the SEER (Surveillance, Epidemiology, and End Results) database. The patients were allocated randomly to a training cohort and validation cohort. Variables were selected using a backward stepwise method in a Cox regression model. Based on the predictive model with the identified prognostic factors, nomograms were established to predict the 3-, 5-, and 8-year survival OS and CSS rates of LSCC patients. The accuracy of the nomograms was evaluated based on the consistency index (C-index), while their prediction accuracy was evaluated using calibration plots. Decision curve analyses (DCAs) were used to evaluate the performance of our survival model.

Results: The multivariate analyses demonstrated that age at diagnosis, marital status, sex, race, American Joint Committee on Cancer stage, surgery status, and radiotherapy status were risk factors for both OS and CSS. The C-index, area under the time-dependent receiver operating characteristic curve, and calibration plots demonstrated
INTRODUCTION

Cancer of the lips accounts for more than 25% of all oral cancers, and approximately 90%-93% of cases are squamous cell carcinoma (SCC). According to the Surveillance, Epidemiology, and End Results (SEER) statistics fact sheet on lip cancer (https://seer.cancer.gov/statfacts/html/lip.html; accessed January 4, 2019), the number of new cases in 2015 was estimated at 70,000, and the estimated death toll was 2,000. Although the mortality rate is low for SCC, such carcinomas are more likely to cause damage by local invasion or cervical lymph node metastasis.

The American Joint Committee on Cancer (AJCC) staging system has been widely used to determine treatment strategies for lip squamous cell carcinoma (LSCC) patients. This system is commonly used alone to predict the prognosis for an ensemble population of patients, and it has some crucial limitations since the prognosis of LSCC patients is influenced by many other factors such as race, marital status, and age. Ignoring these significant prognostic factors may decrease the accuracy of survival predictions, including since the survival outcomes of patients at the same AJCC stage can be vary widely. The clinical uniqueness of LSCC means that new prognostic tools are needed to increase the accuracy of survival predictions in LSCC patients.

A nomogram is a convenient diagrammatic representation of a mathematical model that combines various key variables to forecast a specific outcome. Nomograms have been widely used to help surgeons develop treatment plans and assess the prognosis of various types of cancer and National Comprehensive Cancer Network guidelines have introduced nomograms that perform well. The aim of the present study was to establish a comprehensive prognostic evaluation system for LSCC and validate its prediction accuracy.

METHODS

2.1 Patient selection

We investigated information on patients in the latest version of the SEER (covering 18 registries), by using SEER*Stat version 8.3.5 (https://seer.cancer.gov/). We searched the ICD-O-3 (third edition of the International Classification of Cancer Diseases) for the histological type codes of 8070-8078 for SCC. Cases that were not confirmed by microscopy or only in an autopsy were excluded, as were those with unknown or incomplete variables. The examined variables included marital status, AJCC stage, age, race, sex, surgery status, radiotherapy status, tumor site, vital status, and cause-specific death. We applied the sixth edition of the AJCC staging system, and we restricted our search to between 2004 and 2015 since the system was published in 2004.

There were 6,603 qualified patients identified in the SEER database, of which 4,175 were available after the application of a strict screening process. For the construction and validation of the nomograms, we randomly distributed 70% of the patients to the training cohort (n = 2,922) and 30% to the validation cohort (n = 1,253).

The main outcomes were overall survival (OS) and cancer-specific survival (CSS). OS was defined as the interval from an LSCC diagnosis to the last follow-up or death, without restriction as to the cause of death, while CSS was defined as the interval from an LSCC diagnosis to death due to LSCC or a review of the death status (if a patient was alive at the last follow-up or dead from other causes). All data from the SEER database are freely available.

2.2 Statistical analysis

The eight pathological and clinical characteristics of age at diagnosis, marital status, race, tumor site, sex, AJCC stage, radiotherapy status, and surgery status were used to conduct the analyses. Continuous variables were expressed as mean ± SD values if they conformed to a Gaussian distribution; otherwise they were expressed as median (25th-75th percentile) values. Categorical variables were expressed as percentages. The method of backward stepwise selection in a Cox regression model was applied to the training cohort to select variables. Based on the predictive model of prognostic factors, two nomograms were constructed for the incidence rates of OS and CSS in LSCC patients over 3, 5, and 8 years.

Conclusions: We have developed and validated LSCC prognosis nomograms for OS and CSS for the first time. These nomograms can be valuable tools for clinical practice when clinicians are helping patients to understand their survival risk for the next 3, 5, and 8 years.

KEYWORDS
cancer-specific survival, lip squamous cell carcinoma, nomogram, overall survival, SEER
2.3 Validation of the nomograms

The nomograms were tested by measuring calibration and differentiation curves for both the training cohort (internally) and the validation cohort (externally). The prediction accuracy of each nomogram was evaluated by the consistency index (C-index) and the area under the time-dependent receiver operating characteristic curve (AUC). Calibration plotting was used to evaluate the agreement between the actual outcome and the predicted probability. There were two lines in the calibration plots: one was the data line and the other was a 45-degree reference line; the discrepancy between these two lines reflects the accuracy of a nomogram.

Both discrimination and calibration were evaluated using bootstrapping with 500 resamples. Decision curve analyses (DCAs) were conducted to test the clinical value of the predictive models. All of the statistical analyses were performed using SPSS software (version 24.0, SPSS, Chicago, IL, USA) and R software. A two-sided probability value of \( P \leq 0.05 \) was deemed to indicate statistical significance.

3 RESULTS

3.1 Patient characteristics

The 4175 LSCC patients screened from the SEER database were divided using the popular random split-sample method (with a split ratio of 7:3) into 2922 in the training cohort and 1253 in the validation cohort. The median age at the time of diagnosis was 69 years in the training cohort and 67 years in the validation cohort. Most of the patients were married (73.4%), male (96.0%), and at AJCC stage I (78.8%). The two cohorts comprised 81.8% of patients with tumors located on the lower lip, 10.1% with tumors on the upper lip, and 8.1% with tumors in the oral commissure. Most patients (n = 3881, 93.0%) received surgery while 3712 (88.9%) refused radiotherapy. The median follow-up times were 50 and 51 months in the training and validation cohorts, respectively. The demographics and tumor characteristics of the patients are summarized in Table 1.

3.2 Variable screening

After performing a univariate Cox regression analysis, data on the variables of marital status, age, sex, race, AJCC stage, surgery status, and radiotherapy status were entered into multivariate Cox regression analyses of OS. These multivariate analyses demonstrated that the age at diagnosis (hazard ratio [HR]=1.068, \( P < 0.001 \)), being female (HR = 0.800 vs male, \( P = 0.005 \)), being black (HR = 1.983 vs white, \( P = 0.012 \)), AJCC stage II (HR = 1.294 vs AJCC stage I, \( P = 0.012 \)), AJCC stage III (HR = 2.316 vs AJCC stage I, \( P < 0.001 \)), AJCC stage IV (HR = 4.367 vs AJCC stage I, \( P < 0.001 \)), not receiving surgery (HR = 1.515 vs surgery, \( P = 0.003 \)), and not receiving radiotherapy (HR = 1.573 vs radiotherapy, \( P = 0.062 \)) were risk factors for OS (Table 2).

The multivariate analyses of CSS demonstrated that the age at diagnosis (HR = 1.030, \( P < 0.001 \)), being black (HR = 2.413 vs white, \( P = 0.043 \)), being unmarried (HR = 0.542 vs married, \( P = 0.035 \)), AJCC stage II (HR = 2.182 vs AJCC stage I, \( P = 0.002 \)), AJCC stage III (HR = 6.745 vs AJCC stage I, \( P < 0.001 \)), AJCC stage IV (HR = 15.981 vs AJCC stage I, \( P < 0.001 \)), and not receiving surgery (HR = 2.128 vs surgery, \( P < 0.001 \)) were risk factors for CSS (Table 3).

3.3 Prognostic nomograms for OS and CSS

Based on selected variables with HRs, a nomogram was established that contains all of the important independent factors for predicting the 3-, 5-, and 8-year OS rates in the training cohort.
The OS nomogram indicated that the age was the strongest factor influencing the prognosis, followed by the AJCC stage, race, surgery status, sex, and radiotherapy status (Figure 1A). The nomogram for predicting the 3-, 5-, and 8-year CSS rates was developed using the same method (Figure 1B). In the CSS nomogram, the AJCC stage was the strongest influencing factor, followed by age, race, surgery, and marital status.

Each variable is given a score on the points scale of each nomogram. The scores for all of the variables are added to obtain the total score, and a vertical line is dropped down from the total-points row to estimate the probability of surviving for 3, 5, and 8 years.

### 3.4 | Performance of the nomograms

The C-index for the OS nomogram was 0.748 in the training cohort and 0.723 in the validation cohort. The AUC values for the training cohort (0.769, 0.792, and 0.797 for the 3-, 5-, and 8-year OS, respectively) and validation cohort (0.826, 0.807, and 0.739) indicated the good discriminative ability of the model also for the CSS nomogram (Figure 2A,B). Calibration plots of the OS and CSS nomograms showed that the predicted 3-, 5-, and 8-year survival probabilities for the training and validation cohorts were almost identical to the actual observations (Figures 3 and 4).

### 3.5 | Decision curve analysis

The 3-, 5-, and 8-year DCA curves indicated that both models yielded net benefits in the training and validation cohorts (Figures 5 and 6).

### 4 | DISCUSSION

LSCC is a common malignant tumor of the head and neck that accounts for about 30% of oral cancers. The rate of cervical metastasis from SCC of the lip reportedly ranges from 4% to 15%. However, there is insufficient information for predicting the OS and CSS in patients with LSCC. Although the AJCC staging system has significant predictive power for the prognosis of LSCC patients, it does not include some important risk factors such as sex,

---

**TABLE 2** Selected variables by multivariate Cox regression analysis (training cohort) OS

| Variables     | Multivariate analysis | P-value |
|---------------|----------------------|---------|
| Age at diagnosis | 1.068 1.062-1.074 | <0.001 |
| Sex           |                       |         |
| Male          | Reference             |         |
| Female        | 0.800 0.684-0.935     | 0.005   |
| Race          |                       |         |
| White         | Reference             |         |
| Black         | 1.983 1.159-3.393     | 0.012   |
| Others        | 0.573 0.323-1.016     | 0.056   |
| AJCC          |                       |         |
| I             | Reference             |         |
| II            | 1.294 1.054-1.589     | 0.014   |
| III           | 2.316 1.750-3.065     | <0.001  |
| IV            | 4.367 3.317-5.751     | <0.001  |
| Surgery       |                       |         |
| Yes           | Reference             |         |
| No            | 1.515 1.154-1.988     | 0.003   |
| Radiotherapy  |                       |         |
| Yes           | Reference             |         |
| No            | 1.257 0.987-1.597     | 0.062   |

**TABLE 3** Selected variables by multivariate Cox regression analysis (training cohort) CSS

| Variables     | Multivariate analysis | P-value |
|---------------|----------------------|---------|
| Age at diagnosis | 1.030 1.017-1.043 | <0.001 |
| Race          |                       |         |
| White         | Reference             |         |
| Black         | 2.413 1.027-5.668    | 0.043   |
| Others        | 1.117 0.454-2.749    | 0.810   |
| Marital status|                       |         |
| Married       | Reference             |         |
| Unmarried     | 0.542 0.306-0.958    | 0.035   |
| Others        | 1.181 0.708-1.970    | 0.525   |
| AJCC          |                       |         |
| I             | Reference             |         |
| II            | 2.182 1.338-3.560    | 0.002   |
| III           | 6.745 4.016-11.323   | <0.001  |
| IV            | 15.981 10.326-24.733 | <0.001  |
| Surgery       |                       |         |
| Yes           | Reference             |         |
| No            | 2.128 1.337-3.384    | 0.001   |

Abbreviations: AJCC, American Joint Committee on Cancer; CI, confidence interval; CSS, cancer-specific survival; HR, hazard ratio.
marital status, age, race, surgery status, and radiotherapy status. In contrast to the AJCC staging system being based on assessments of the prognosis in risk groups, we sought to develop and validate predictive nomograms for predicting the 3-, 5-, and 8-year OS and CSS rates in individual LSCC patients. By including readily available and important prognostic factors, such nomograms can provide quantifiable prognostic predictions for each patient.\textsuperscript{20}

The proposed nomograms are easy-to-use clinical tools that will facilitate the promotion of patient counseling and personalized treatments. As an example, consider the following two LSCC patients at AJCC stage III: patient 1 is a 69-year-old black married male who received surgery only, while patient 2 is a 58-year-old white unmarried female who underwent both surgery and radiation. Applying the AJCC staging manual would produce the identical prognosis for both of these patients.\textsuperscript{21} However, the results obtained by applying our new nomograms are different: the 3-, 5-, and 8-year predicted OS rates were 45%, 24%, and 10%, respectively, for patient 1, and 85%, 77%, and 63% for patient 2; the corresponding CSS rates were 66%, 53%, 48%, 94%, 90%, and 86%, respectively. Furthermore, the eighth version of the AJCC staging system indicates that prognoses would be evaluated while also considering nomograms in future versions.\textsuperscript{22}

The nomograms proposed in the present study contain several independent prognostic factors that are conventionally used in clinical practice. Age has the highest score in both nomograms. Multivariable analyses have found older age to be an independent risk variable for both OS and CSS, clearly indicating that older patients have a lower survival rate.\textsuperscript{23-25} Also, a higher AJCC stage has been associated with greater harm to patient survival.\textsuperscript{21} Our study found the same tendencies, with the nomogram score increasing with the AJCC stage. However, our two nomograms indicated that the AJCC

![Nomogram predicting 3-, 5-and 8-y OS](image1)

![Nomogram predicting 3-, 5-and 8-y CSS](image2)
stage is the second most important factor for OS but the first most important one for CSS. This finding is reasonable given that CSS is focused specifically on the cancer itself.

We found that the OS was higher for females than for males (Table 2), whereas there was no statistically significant sex-related difference in CSS (Table 3). This outcome resembles previous findings. Males are more likely to drink alcohol and smoke, which are closely associated with not-cancer-specific death. LSCC most commonly affects white individuals, accounting for 96% of all cases in the present study, but most of them had a good prognosis.

Studies of African Americans have found that the overall incidence of SCC is lower in the head and neck, while the incidence of more aggressive and advanced mutations is higher, which may contribute to a higher HR. This is also consistent with our results. Surgery is generally recommended as a first-line treatment for lip carcinoma, and surgical resection with negative margins is the mainstay remedy for LSCC, and both the OS and CSS nomograms show the same importance of surgery as an individual predictive factor.

We have developed easy-to-use nomograms for predicting OS and CSS in LSCC patients at 3, 5, and 8 years. Our nomogram model contains risk factors that are readily available and collected through historical records. The clinical applicability and ease of use are among the most important advantages of the nomograms that we have constructed.

We validated the accuracy of our new nomograms using the C-index and calibration curves in both a modeling cohort (internally) and validation cohort (externally). The C-indexes for the 3-, 5-, and 8-year OS and CSS rates were 0.748 and 0.783, respectively, in the internal validation, and 0.723 and 0.799 in the external validation. All of these C-indexes exceed 0.7, and there was excellent coherence between the calibration curves and the 45-degree ideal lines (Figure 2). The plots resembling 45-degree lines indicate that the nomogram predictions were well calibrated both in the training and verification cohorts (Figures 3 and 4).

Some studies have demonstrated the benefits of the latest method of DCA and recommend its use. The results of our study showed that the 3-, 5-, and 8-year DCA curves for both OS and CSS indicate the net benefits with a good performance in both the training and validation cohorts.

4.1 Limitations

The present study based on a large population had some strength, but certain limitations also need to be addressed. First, there was no information about the use of different surgical procedures (neck dissection or other) in the SEER database, or certain important clinical pathological parameters related to prognosis including vascular invasion and the surgical margin. Second, information about some prognostic factors such as chemotherapy and tumor
markers such as EGFR, HPV, and P53 is also not available. Third, the nomograms were established using retrospective data obtained from the SEER database, which is associated with the potential hazard of selection bias. Finally, the predicted values calculated using the nomogram are for reference use by clinicians only, rather than representing absolutely accurate prognoses. We plan to perform future prospective studies to test the nomograms with the aim of compensating for these limitations.

5 | CONCLUSIONS

Using a large population-based cohort, we have established and validated two nomograms for estimating the 3-, 5-, and 8-year OS and CSS rates in patients with LSCC for the first time. These nomograms were found to be accurate and show strong predictive power in both internal and external validation tests. They are precise and easy to implement, and hence can provide clinicians with reference information for determining personalized clinical treatment options and providing personalized prognoses.

CONFLICT OF INTEREST

The author reports no conflict of interest in this work.

DATA AVAILABILITY STATEMENT

I confirm that my article contains a Data Availability Statement even if no data are available (list of sample statements) unless my article type does not require one. I confirm that I have included a citation for available data in my references section, unless my article type is exempt.

ORCID

Jun Lyu https://orcid.org/0000-0002-2237-8771

REFERENCES

1. Han AY, Kuan EC, Mallen-St Clair J, Alonso JE, Arshi A, St John MA. Epidemiology of squamous cell carcinoma of the lip in the United States: a population-based cohort analysis. *JAMA Otolaryngol Head Neck Surg*. 2016;142(12):1216-1223.
2. Zitschii R, Park C, Renner G, Reajr J. Outcome analysis for lip carcinoma. *Otolaryngol Head Neck Surg*. 1995;113(5):589-596.
3. Ahmed MM, Moore BA, Schmalbach CE. Utility of head and neck cutaneous squamous cell carcinoma sentinel node biopsy: a systematic review. *Otolaryngol Head Neck Surg*. 2014;150(2):180-187.
4. Petersen PE. Oral cancer prevention and control—the approach of the World Health Organization. *Oral Oncol*. 2009;45(4–5):454-460.
5. Warnaokusurya S. Global epidemiology of oral and oropharyngeal cancer. *Oral Oncol*. 2009;45(4–5):309-316.
6. Weinberger PM, Merkley M, Lee JR, et al. Use of combination proteomic analysis to demonstrate molecular similarity of head and neck squamous cell carcinoma arising from different subsites. *Arch Otolaryngol Head Neck Surg*. 2009;135(7):694-703.
7. Cherobin A, Wainstein A, Colosimo EA, Goulart E, Bittencourt FV. Prognostic factors for metastasis in cutaneous melanoma. *An Bras Dermatol*. 2018;93(1):19-26.
8. Weiss SA, Hanniford D, Hernando E, Osman I. Revisiting determinants of prognosis in cutaneous melanoma. *Cancer*. 2015;121(23):4108-4123.
9. Zhang G, Wu Y, Zhang J, et al. Nomograms for predicting long-term overall survival and disease-specific survival of patients with clear cell renal cell carcinoma. *Onco Targets Ther*. 2018;11:5535-5544.
10. Cho J-K, Lee G-J, Yi K-I, et al. Development and external validation of nomograms predictive of response to radiation therapy and overall survival in nasopharyngeal cancer patients. *Eur J Cancer*. 2015;51(10):1303-1311.
11. Li J, Liu Y, Yan Z, et al. A nomogram predicting pulmonary metastasis of hepatocellular carcinoma following partial heptectomy. *Br J Cancer*. 2014;110(5):1110-1117.
12. Liu J, Geng Q, Liu Z, et al. Development and external validation of a prognostic nomogram for gastric cancer using the national cancer registry. *Onco tgt*. 2016;7(24):35853-35864.
13. Kawachi MH, Bahnson RR, Barry M, et al. NCCN clinical practice guidelines in oncology: prostate cancer early detection. *J Natl Compr Canc Netw*. 2010;8(2):240-262.
14. Song W, Lv C-G, Miao D-L, et al. Development and validation of a nomogram for predicting survival in patients with gastrointestinal stromal tumours. *Eur J Surg Oncol*. 2018;44(10):1657-1665.
15. Wang F, Zhang H, Wen J, et al. Nomograms forecasting long-term overall and cancer-specific survival of patients with oral squamous cell carcinoma. *Cancer Med*. 2018;7(4):943-952.
16. Kornevs E, Skagers A, Tars J, Bigestans A, Lauskis G, Libermanis O. 5 year experience with lower lip cancer. *Stomatologija*. 2005;7(3):95-98.
17. Salgarelli AC, Sartorelli F, Cangiano A, Pagani R, Collini M. Surgical treatment of lip cancer: our experience with 106 cases. *J Oral Maxillofac Surg*. 2009;67(4):840-845.
18. Wermker K, Belok F, Schipmann S, Klein M, Schulze H-J, Hallermann C. Prediction model for lymph node metastasis and recommendations for elective neck dissection in lip cancer. *J Cranio maxillofac Surg*. 2015;43(4):545-552.
19. Unsal AA, Unsal AB, Henn TE, Baredes S, Eloy JA. Cutaneous squamous cell carcinoma of the lip: a population-based analysis. *Laryngoscope*. 2018;128(1):84-90.
20. Li Y, Zhao Z, Liu X, et al. Nomograms to estimate long-term overall survival and tongue cancer-specific survival of patients with tongue squamous cell carcinoma. *Cancer Med*. 2017;6(5):1002-1013.
21. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*. 2010;17(6):1471-1474.
22. Lydiatt WM, Patel SG, O'Sullivan B, et al. Head and neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. *CA Cancer J Clin*. 2017;67(2):122-137.
23. Shen W, Sakamoto N, Yang L. Cancer-specific mortality and competing mortality in patients with head and neck squamous cell carcinoma: a competing risk analysis. *Ann Surg Oncol*. 2015;22(1):264-271.
24. Skillington SA, Kallogjeri D, Lewis JS, Piccirillo JF. Prognostic importance of comorbidities and the association between comorbidity and p16 in oropharyngeal squamous cell carcinoma. *JAMA Otolaryngol Head Neck Surg*. 2016;142(6):568-575.
25. Wray CJ, Phatak UR, Robinson EK, et al. The effect of age on race-related breast cancer survival disparities. *Ann Surg Oncol*. 2013;20(8):2541-2547.
26. Bischof DA, Kim Y, Behman R, et al. A nomogram to predict disease-free survival after surgical resection of GIST. *J Gastrointest Surg.* 2014;18(12):2123-2129.

27. Osazuwa-Peters N, Massa ST, Christopher KM, Walker RJ, Varvares MA. Race and sex disparities in long-term survival of oral and oropharyngeal cancer in the United States. *J Cancer Res Clin Oncol.* 2016;142(2):521-528.

28. Peterson CE, Khosla S, Chen LF, et al. Racial differences in head and neck squamous cell carcinomas among non-Hispanic black and white males identified through the National Cancer Database (1998–2012). *J Cancer Res Clin Oncol.* 2016;142(8):1715-1726.

29. Dougherty W, Givi B, Jameson MJ. AHNS series - do you know your guidelines? *Lip cancer. Head Neck.* 2017;39(8):1505-1509.

30. Belcher R, Hayes K, Fedewa S, Chen AY. Current treatment of head and neck squamous cell cancer. *J Surg Oncol.* 2014;110(5):551-574.

31. Rousson V, Zumbrunn T. Decision curve analysis revisited: overall net benefit, relationships to ROC curve analysis, and application to case-control studies. *BMC Med Inform Decis Mak.* 2011;11:45.

32. Vickers AJ, Elkin EB. Decision curve analysis: a novel method for evaluating prediction models. *Med Decis Making.* 2006;26(6):565-574.

33. Larsen SR, Johansen J, Sørensen JA, Krogdahl A. The prognostic significance of histological features in oral squamous cell carcinoma. *J Oral Pathol Med.* 2009;38(8):657-662.

34. Perrone F, Bossi P, Cortelazzi B, et al. TP53 mutations and pathologic complete response to neoadjuvant cisplatin and fluorouracil chemotherapy in resected oral cavity squamous cell carcinoma. *J Clin Oncol.* 2010;28(5):761-766.

35. Zanotti L, Pardero A, Piazza C, et al. Epidermal growth factor receptor detection in serum and saliva as a diagnostic and prognostic tool in oral cancer. *Laryngoscope.* 2017;127(11):E408-E414.

**How to cite this article:** Hu C-Y, Pan Z-Y, Yang J, et al. Nomograms for predicting long-term overall survival and cancer-specific survival in lip squamous cell carcinoma: A population-based study. *Cancer Med.* 2019;8:4032-4042. [https://doi.org/10.1002/cam4.2260](https://doi.org/10.1002/cam4.2260)

**APPENDIX**

**FIGURE A1** OS calibration plots. Show the relationship between the predicted probabilities base on the nomogram and actual values of the train set (A-C) and validation set (D-F). OS, overall survival.
**FIGURE A2** CSS Calibration plots. Show the relationship between the predicted probabilities based on the nomogram and actual values of the train set (A-C) and validation set (D-F). CSS, cancer-specific survival.
FIGURE A3  Decision curve analysis (DCA) of overall survival (OS)
In the figure, the abscissa is the threshold probability, the ordinate is the net benefit rate. The horizontal one indicates that all samples are negative and all are not treated, with a net benefit of zero. The oblique one indicates that all samples are positive. The net benefit is a backslash with a negative slope. A-C, Came from the training set, and (D-F) came from the validation set.
FIGURE A4  Decision curve analysis (DCA) of cancer-specific survival (CSS)  
In the figure, the abscissa is the threshold probability, the ordinate is the net benefit rate. The horizontal one indicates that all samples are negative and all are not treated, with a net benefit of zero. The oblique one indicates that all samples are positive. The net benefit is a backslash with a negative slope. A-C, Came from the training set, and (D-F) came from the validation set.